Headlines about MediciNova (NASDAQ:MNOV) have trended positive recently, according to Accern Sentiment. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. MediciNova earned a media sentiment score of 0.27 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 51.3328727296623 out of 100, meaning that recent media coverage is somewhat likely to have an effect on the stock’s share price in the next several days.

MediciNova (NASDAQ MNOV) traded up $0.35 during trading on Tuesday, hitting $7.66. The stock had a trading volume of 174,700 shares, compared to its average volume of 66,114. MediciNova has a fifty-two week low of $4.40 and a fifty-two week high of $7.88. The stock has a market cap of $263.90, a P/E ratio of -23.94 and a beta of 0.04.

MediciNova (NASDAQ:MNOV) last posted its earnings results on Monday, October 23rd. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.02). equities research analysts predict that MediciNova will post -0.37 earnings per share for the current year.

Separately, BidaskClub raised MediciNova from a “hold” rating to a “buy” rating in a report on Wednesday, January 10th.

TRADEMARK VIOLATION WARNING: “MediciNova (MNOV) Getting Positive Media Coverage, Report Shows” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://theolympiareport.com/2018/01/23/medicinova-mnov-getting-positive-media-coverage-report-shows-2.html.

MediciNova Company Profile

Medicinova, Inc is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin).

Insider Buying and Selling by Quarter for MediciNova (NASDAQ:MNOV)

Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.